Barclays analyst Matt Miksic maintains $Edwards Lifesciences (EW.US)$ with a buy rating, and adjusts the target price from $80 to $85.
According to TipRanks data, the analyst has a success rate of 62.2% and a total average return of 7.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences reported robust sales and earnings, surpassing expectations. The guidance provided for Q4 and the outlook towards 2025 are anticipated to sustain the stock's upward trajectory.
The firm believes that it will require several more quarters for Edwards Lifesciences to persuade investors that it has identified the lowest point for its TAVR franchise, following the third-quarter report.
Expectations were modest prior to the third-quarter results, and the subsequent reports and commentary for the fourth quarter and full year did not suggest that potential negatives were accounted for. Although the slowing trends in fourth-quarter TAVR are attributed to several one-time factors, it's challenging to refute the possibility that TAVR growth may continue to decelerate into the next fiscal year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Matt Miksic維持$愛德華生命科學 (EW.US)$買入評級，並將目標價從80美元上調至85美元。
根據TipRanks數據顯示，該分析師近一年總勝率為62.2%，總平均回報率為7.2%。
此外，綜合報道，$愛德華生命科學 (EW.US)$近期主要分析師觀點如下：
愛德華茲生命科學報告了強勁的銷售和收益，超出了預期。預計爲第四季度提供的指導和2025年的展望將維持該股的上漲勢頭。
該公司認爲，繼第三季度報告發布之後，愛德華茲生命科學還需要幾個季度才能說服投資者相信它已經確定了TAVR系列的最低點。
在第三季度業績公佈之前，預期不大，隨後的第四季度和全年報告和評論並未表明潛在的負面因素已考慮在內。儘管第四季度TAVR的放緩趨勢歸因於幾個一次性因素，但要駁斥TAVR增長可能持續減速到下一財年的可能性具有挑戰性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
